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A phase I/II trial was undertaken to determine maximum tolerated dose
(MTD), toxicity, clinical efficacy, and biological activity of bortezomib in
patients with advanced stage primary or postpolycythemia vera/postessen-
tial thrombocythemia myelofibrosis (MF). Bortezomib (0.8, 1.0, or 1.3 mg/
m2) was administered on days 1, 4, 8, and 11 by intravenous push to
patients previously resistant to at least one line of therapy, or with an inter-
mediate/high-risk score of International Working Group (IWG) [1]. Therapy
was repeated every 28 days for six cycles. At 1.3 mg/m2 dose, one of six
patients experienced a dose limiting toxicity, and this was determined to be
the MTD. Neither remissions nor clinical improvements were recorded in
16 patients treated at this dose level, fulfilling the early stopping rule in the
Simon two-stage study design. Major toxicity was on thrombocytopenia. In
9 of 15 patients bortezomib proved that it is able to reduce bone marrow
vessel density. However, the agent was associated with worsening of
markers of disease activity, such as enhancement of hematopoietic CD34-
positive progenitor cell mobilization, WT-1 gene expression in mononuclear
cells, and downregulation of CXCR4 expression on CD34-positive cells.
Occurrence of both beneficial and detrimental biological effects claims fur-
ther investigation on the mechanisms of the drug in MF.
The proteasome inhibitor bortezomib (Velcade1, Millenniun Pharmaceuticals,
and Johnson & Johnson Pharmaceutical Research and Development, LLC,
Cambridge, MA) induces tumor cell death by inhibiting the degradation of sev-
eral intracellular proteins involved in cell cycle regulation, and inhibits degrada-
tion of IkB blocking the multifunctional transcription factor nuclear factor-kappa
B (NFkB) leading to reduced levels of transforming growth factor b-1 (TGF-b1).
In addition, bortezomib indirectly inhibits angiogenesis and prevents tumor
adaptation to hypoxia by functional inhibition of hypoxia inducible factor 1-alpha
(HIF-1a). In MF, several lines of evidence are in favor of a crucial role of the
TGF-b1, which is released by clonal proliferation of megakaryocytes or mono-
cytes via activation of NF-kB [2,3]. Moreover, MF shows enhanced bone mar-
row and spleen angiogenesis that has been documented to be associated with
worse prognosis [4,5]. Thus, NF-kB signaling pathway and angiogenesis are
candidate targets for bortezomib in MF. Based on these assumptions, in 2007
we initiated a phase I/II trial with the aim to evaluate the safety and efficacy of
bortezomib in patients with MF, to evaluate its effect on bone marrow angiogen-
esis and fibrosis, and on biomarkers of severity and progression of the disease.
Twelve patients were enrolled onto phase I of the study. The baseline
characteristics of these patients are listed in Table I. Three patients treated
at the 0.8 mg/m2 dose level, and three treated at the 1 mg/m2 dose level
had no dose limiting toxicity (DLT). One of six patients treated at the 1.3
mg/m2 dose level experienced acute severe pulmonary distress syndrome
during the first cycle of treatment and this dose level was defined as MTD.
Sixteen patients were enrolled onto the phase II portion of the study. One
patient did not complete the first cycle of treatment, 13 patients (81%) com-
pleted four cycles of treatment, and nine (56%) patients completed the six
cycles of treatment. The primary reason for early withdrawal from the study
was unacceptable adverse events (AEs) (three patients), patient’s refusal
(two patients), and physician’s decision (two patients).
At intention to treat analysis in which all patients who received at least
one dose of the drug in the phase II study were evaluable (16 patients), no
responses were recorded according the IWG response criteria [6]. At the
per protocol analysis in which patients who received at least four cycles of
treatment were evaluable, 13 of the 16 patients in the phase II study were
evaluable. No patient had clinical improvement. As a matter of fact, no
patient had Hb increasing >2 g/dL by the end of the study, and none of the
transfusion-dependent patients (n 5 4) had decrease in blood transfusion
need. One patient with absolute neutrophil count below 1 3 109/L at baseline
did not increase neutrophil count by at least 100%. None of the patients had
>50% spleen reduction. A patient with 4,448 3 109/L platelet count at base-
line decreased the platelet count by 67% by the end of the study, but this
response is not included in the criteria for clinical improvement. As depicted in
Table II, the most frequent Grade 3 or 4 toxicity was thrombocytopenia.
At analysis of individual changes in cellularity, CD341 cell content, and fibro-
sis in the 14 patients who completed the six cycles of treatment at any dose
and had serial bone marrow specimens available for review, no statistically sig-
nificant changes in none of the parameters resulted after therapy. At baseline,
the patients had a significantly higher level of TGF-b1 than our control normal
population (4738 pg/mL vs. 2404 pg/mL; P 5 0.015). No correlation was evi-
denced between baseline bone marrow fibrosis grade and plasma TGF-b1
level. Bortezomib treatment did not significantly decrease total TGF-b1 plasma
levels (TGF-b1 final, 4959.5 pg/mL) from baseline (Wilcoxon test, P 5 NS).
In the whole population of patients, bortezomib treatment did not significantly
reduce the median vessels density, vessels area, and vessels perimeter. How-
ever, a decrease in vessels density was evidenced in 9 of the 15 (60%) patients
studied (Table III). The percent decrease in vessels density ranged from 1.4% to
51%. Vessels area and vessels perimeter were reduced in 40% and 66% of
cases, respectively. At baseline, the median value of plasma vascular endothelial
growth factor (VEGF) in MF patients was 78.9 pg/mL (range, from 15.6 to 236.4
pg/mL), significantly higher than in normal controls (median, 30.16 pg/mL; range,
from 15.6 to 130.6 pg/mL; P 5 0.001). Bortezomib treatment did not significantly
decrease VEGF levels from baseline (Wilcoxon test, P5 NS).
At analysis of the 17 patients who completed at least four cycles of treatment at
any dose, and had serial measurements available, the median baseline hemato-
poietic CD341 cell number was 114.1 3 106/L (range, 15.5 to 3026 3 106/L),
whereas it was 143.1 3 106/L (range, 17.2 to 3688.3 3 106/L) at the end of the
study (Wilcoxon test, P 5 0.05). Increase in CD341 cells in peripheral blood at
the end of the study was detected in 11 of 17 (64.7%) patients, and the increase
at the end of the therapy ranged from 4% to 1125% of basal value.
At analysis of the 14 patients who completed at least four cycles of treatment
at any dose, and had serial measurements available, median WT1 expression
at baseline was 6,870.68 copies/104 ABL copies (range, 221.31 to 67,842.21
copies). After bortezomib, median WT1 expression did not significantly change
(Wilcoxon test, NS). However, WT-1 expression increased in 8 of 14 patients
(57.1%) with an increase ranging from 10% to 820% of basal value.
At analysis of the 18 patients who completed at least four cycles of treat-
ment at any dose, CXCR4 expression on circulating CD34-positive cells was
downmodulated at baseline in patients involved in this study (median, 22%;
range, 6.2–92%), as compared with our historical normal controls (median,
76.7%; range 37–97%; P < 0.001). By the end of the study, the value of
CXCR4 expression was significantly lower than at baseline (median, 15.2%;
range, 5.9–90%; Wilcoxon test, P 5 0.05). Reduction was documented in
10 of the 18 patients analyzed (55.7%). Granulocyte DNA-derived JAK2
617F allele burden was measured in 13 patients at baseline and after com-
pletion of at least four cycles of treatment. Twelve patients were JAK2V617F
mutated with a median allele burden of 42.5% (range 4–100%). In none of
the patients, the V617F burden variation was >10%. No significant changes
in plasma SDF-1, IL-8, IL-6, and TNF were revealed at the end of the study.
In summary, with this phase I/II study, we found that none of the
22 patients either treated with the MTD of 1.3 mg/m2, or with lower doses in
the phase I of the study, achieved a clinical response. Our results are in
agreement with the lack of any clinical efficacy described by Mesa et al.
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who reported the results of a pilot phase II study with bortezomib in nine
patients with MF and two with systemic mastocytosis or chronic myelomono-
cytic leukemia, showing lack of any clinical efficacy of the drug [7].
The results of this trial contrast with the 31–80% response rate in multiple
myeloma [8], mantle-cell lymphoma [9], amyloidosis [10], cutaneous T-cell
lymphoma [11], Waldestrom macroglobulinemia [12], or mucosa-associated
lymphoid tissue (MALT) lymphoma [13] when bortezomib was used as single
agent. In an attempt to clarify how bortezomib affects the pathogenetic
mechanisms that sustain MF, in this trial we evaluated bone marrow and
blood biomarkers variations as secondary endpoints of the study. In a great
proportion of patients, the density of bone marrow microvessels was less
after treatment than at baseline, reaching up to 51% reduction. The role of
proteasome inhibition in angiogenesis has been documented in several pre-
clinical studies [14–17] and one in vivo study in humans [18]. We were not
able to document that the effect on angiogenesis could be associated with a
decrease of plasma VEGF. This was in accordance with the results in multi-
ple myeloma [19].
In contrast with the potentially beneficial effect on angiogenesis, we docu-
mented that the therapy had the potential to exert detrimental effects on bio-
markers that mirror disease activity and progression. CXCR4 downregulation
seems to represent the most relevant biological consequence of bortezomib
therapy in patients with MF. Downregulation of cell surface proteins is a gen-
eral mechanism of bortezomib [20–22]. However, the decrease of CXCR4 on
CD341 cells of patients with MF seems to be an unique example of chemo-
kine receptor downregulation, because bortezomib has no effect on CXCR4
expression in multiple myeloma cells [23]. Furthermore, because the downre-
gulation of the above-mentioned receptors on the cell surface is potentially
beneficial, such as overcoming cell adhesion-mediated drug resistance for
VLA-4 downregulation [21], in MF CXCR4 downregulation exacerbates a detri-
mental disease characteristic that specifically is responsible for hematopoietic
cell mobilization and myelopoiesis derangement. We hypothesize that the
strong influence of bortezomib on the bone marrow microenvironment may
interact with the migration and adhesion mechanisms of hematopoietic stem
cells operating in MF, and disrupt a homeostatic equilibrium that is unique and
specific for the disease. A better understanding of these mechanisms is nec-
essary for planning a better targeted use of bortezomib in MF.
Methods
Study design
For the Phase I portion of the study, DLT was defined as any Grade 3 or
4 treatment-related nonhematologic toxicity (National Cancer Institute Com-
mon Terminology Criteria of Adverse Events, version 3.0); any Grade 4
treatment-related hematologic toxicity; or any Grade 3 treatment-related
hematologic toxicity requiring treatment delay of more than 2 weeks. Three
patients were to be enrolled at each dose level starting at dose level 1. If no
DLT was observed in cycle one, three patients were enrolled at the next
TABLE I. Baseline Characteristics of the Study Populations
Entering the Phase I and Phase II of the Study
Characteristic
Phase I (N 5 12) Phase II (N 5 16)
No of
patients
(%)
Median
(range)
No of
patients
(%)
Median
(range)
Age, years 57 (22–69) 58 (46–72)
Sex
Female 5 (41.7) 6 (37.5)
Male 7 (58.3) 10 (62.5)
Type of Myelofibrosis
Primary 11 (91.6) 10 (62.5)
Post-PV 1 (8.4) 4 (25)
Post-ET 0 2 (12.5)
Prior treatment for myelofibrosis
Hydroxyurea 8 (66.6) 13 (81.2)
Splenectomy 1 (8.4) 2 (12.5)
Danazol 1 (8.4) 2 (12.5)
Thalidomide 1 (8.4) 2 (12.5)
Duration of the
disease
(months)
44.5 (1–228) 35 (1–156)
Transfusion
dependent
patients
2 (16.6) 3 (18.7)
Transfusion-
independent
patients with
initial
hemoglobin
<10 g/dL
5 (41.7) 5 (31.2)
White blood cell
count (3109/L)
7.9 (3.7–71.3) 13.2 (1.7–71.3)
Myeloblasts in
peripheral
blood (%)
2 (0–7) 1 (0–7)
Immature
myeloid
cells
(nonblasts)
in peripheral
blood (%)
1 (0–12) 3 (0–15)
Erythroblasts
(% leukocytes)
in peripheral
blood
3 (0–45) 4 (0–45)
Platelet count
(3109/L)
302 (106–1066) 285 (70–3405)
Spleen size
below
the costal
margin, cm
15 (2–20) 15 (2–25)
Dupriez prognostic score
Score 0 4 (33.3) 7 (43.8)
Score 1 6 (50) 6 (37.5)
Score 2 2 (16.7) 3 (18.7)
Serum lactate
dehydrogenase
(mU/mL)
1486 (358–3024) 1408 (489–2658)
Chromosomal abnormalitiesa
Not available 5 (41.7) 7 (43.8)
No
chromosomal
abnormalities
5 (41.7) 4 (25)
Chromosomal
abnormalitiesb
2 (16.7)b 5 (31.2)c
a
In all patients, analysis of chromosomal abnormalities was performed on
peripheral blood; bdel5, del7; cdel20, t(x;20), del6/del14, del5, del7.
TABLE II. Toxicity Summary during Treatment with Bortezomib
Event
All adverse
events
Grade
3 events
Thrombocytopenia 8 3
Fatigue 4 0
Rash 2 0
Pyrexia 3 0
Dyspnoea with pulmonary distress syndrome 1 1
Dyspnoea with pulmonary hypertension 1 1
Cutaneous vasculitis 1 1
Peripheral neuropathy 1 0
Cutaneous infectious ulcer 1 1
TABLE III. Bone Marrow Vessels Density during Bortezomib Trial
in 15 Patients Who Had Serial Bone Marrow Specimens Available
for Review
Case
Bortezomib
dose mg/m2
Number of vessels
(31023m2)
Change from
baseline (%)Baseline Final
1 0.8 1.41 2.54 80.1
2 0.8 2.33 2.78 19.3
3 0.8 2.66 2.17 218.4
4 1 3.32 3.02 29.0
5 1 2.17 2.14 21.4
6 1.3 1.30 2.49 91.5
7 1.3 2.66 1.40 247.4
8 1.3 3.65 1.79 250.9
9 1.3 1.92 2.43 26.5
10 1.3 4.09 3.20 221.8
11 1.3 2.76 2.77 0.4
12 1.3 4.56 3.15 230.9
13 1.3 5.93 3.41 242.5
14 1.3 2.06 2.30 11.6
15 1.3 3.96 2.54 236.1
Median 2.66 2.53 29.03
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dose level. If one DLT was observed, the dose level was expanded to six
patients. If two DLTs were observed, the MTD was exceeded and the pre-
vious dose level was expanded to six patients. The recommended phase II
dose was the highest dose level at which one or less of six patients experi-
enced a DLT. Three dose levels were planned (0.8, 1, and 1.3 mg/m2). No
intra patient dose escalation was allowed.
For the Phase II efficacy analysis, we used an optimum Simon 2 stage
design to test the null hypothesis that the complete or major response rate
was 0.05 versus the alternative that this response rate was 0.20 at an
alpha level of 0.05 with 80% power. At the evaluation of response at
18 weeks, if there were no or one responses (complete or major) of first
16 patients, the trial would be terminated for lack of efficacy. If the trial con-
tinued to a second stage, a total of 30 patients would be studied.
Bortezomib was administered intravenously on days 1, 4, 8, and 11 of a
21-day cycle. A total of six cycles were planned while on study. Dose reduc-
tion was allowed for Grade 3 or 4 thrombocytopenia or any Grade 3 or 4
nonhematologic toxicity.
All patients provided written informed consent. The study protocol was
approved by the ethics committee of the IRCCS Policlinico S. Matteo Founda-
tion, Pavia, and of the Florence University Hospital, Florence. The study was
conducted in accordance with the policies of the MPD Research Consortium.
Bone marrow histology and microvascular proliferation
Bone marrow samples were obtained before treatment and at the patient’s
final evaluation. Cellularity and fibrosis were assessed using the EUMNET score
[24]. The rate of CD341 progenitor cells and degree of microvascular prolifera-
tion were evaluated on sections stained with antiCD34 (mouse monoclonal
Thermo Scientific, Fremont, CA). For microvascular proliferation, sections were
evaluated on five randomly selected fields and images digitally acquired using an
Olympus BX-60 microscope equipped with the DP-70 camera (Olympus Optical
Corporation, Japan). From the total area, the area occupied by bone or eventual
art factual spaces was subtracted, and the absolute number, the perimeter, and
the area of CD34 positive vascular structures, including small vessels but not
arterioles or sinusoids, were measured using CELL^F 2.5 software (Olympus
Soft Imaging Solution, Olympus). All the data were parameterized to 10,000 m2.
Biomarkers
Blood samples for the measure of biomarkers were obtained on day 0 of treat-
ment cycle one and at the patient’s final evaluation. The percentage of circulat-
ing CD34-positive hematopoietic progenitor cells was calculated according to
the guidelines from the International Society of Hematotherapy and Graft Engi-
neering [25]. For plasma TGF-b1 measurement, human TGF-b1 immunoassay
was used (Quantikine kit, R&D Systems). Plasma levels of SDF-1, VEGF, IL-8,
IL-6, and TNF were determined with the appropriate human Quantikine kits from
R&D Systems according to the instructions of the manufacturer. Samples were
assessed in duplicate. Seventeen normal individuals were used as controls for
the cytokine level assays. They were 10 men and 7 women, with a median age
of 49 years (range 32–65 years). Levels of WT1 mRNA were measured on
mononuclear cells according the previously reported method [26]. For CXCR4
expression measurement, cells were stained with specific monoclonal antibod-
ies and analyzed using flow cytometry (Becton Dickson, Oxford, UK) as
described earlier [27]. Analysis of JAK2V617F mutational status and mutated
allele burden was performed as described [28].
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